55
Participants
Start Date
January 29, 2020
Primary Completion Date
May 10, 2023
Study Completion Date
June 30, 2025
Zanubrutinib
Zanubrutinib at 160 mg orally twice daily
Nagoya University Hospital, Nagoya
Toyohashi Municipal Hospital, Toyohashishi
Chiba Cancer Center, Chiba
Matsuyama Red Cross Hospital, Matsuyama
Kurume University Hospital, KurumeShi
National Hospital Organization Hokkaido Cancer Center, Sapporo
Aiiku Hospital, Sapporo
Kobe City Medical Center General Hospital, KobeShi
Kanagawa Cancer Center, Yokohama
National Cancer Center Hospital, ChuoKu
Aomori Prefectural Central Hospital, Aomori
Gifu Municipal Hospital, Gifu
The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki
National Hospital Organization Okayama Medical Center, Okayama
Lead Sponsor
BeiGene
INDUSTRY